Organon Pharma Indonesia Tbk. vs Tunas Alfin Tbk. — how do they compare? Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B), while Tunas Alfin Tbk. trades at Rp710 (market cap 927.1B, 392.7K 24h volume). The key difference: Tunas Alfin Tbk. is far larger — about 8.9× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| SCPI | TALF | |
|---|---|---|
Market Cap | 104.4B | 927.1B |
Volume | — | 392.7K |
Lot | — | 3.93K |
Turnover | — | 279.69M |
Average Price | — | 712.23 |
Value | — | 279.69M |
Indicative Equilibrium Price | — | 710 |
Indicative Equilibrium Volume | — | 5 |
Trailing returns across standard periods
Latest headlines on both assets
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →PT Tunas Alfin Tbk (the Company) was founded in 1977 and is based in Jakarta, Indonesia. With one of the largest production capacities, and some of the most advanced equipment and technologies in the region, the Company has also grown into one of the leading integrated fine and Fast Moving Consumer Goods (FMCG) packaging companies in Asia.The Company is currently capable of undertaking several coating processes such as Silicone, Hot Melt, Extrusion, Pressure/Self-Adhesive, Wax Coating and Anti-fungus Coating.
Read more on TALF →